Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Business Wire
Company asserts that Geneoscopy will infringe patented technology central to its Cologuard colorectal cancer screening test MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy’s (defendant) motion to dismiss a patent infringement lawsuit filed by Exact Sciences (plaintiff) in the United States District Court for the District of Delaware. This ruling paves the way for Exact Sciences to seek relief for Geneoscopy’s future infringement and false advertising.Exact Sciences filed the lawsuit in November 2023 to prevent Geneoscopy from infringing upon Exact Sciences’ intellectual property central to its Cologuard® colorectal cancer screening test and to put an end to Geneoscopy’s false and misleading advertising and promotion about the alleged clinical performance and superiority of ColoSense. Rather than answer for its misconduct, Geneoscopy
Show less
Read more
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at BTIG Research from $80.00 to $70.00. They now have a "buy" rating on the stock.MarketBeat
- Exact Sciences: Still No Reason To Own [Seeking Alpha]Seeking Alpha
- Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Exact Sciences (NASDAQ:EXAS) shareholders have endured a 63% loss from investing in the stock three years ago [Yahoo! Finance]Yahoo! Finance
- UltraSight and Mayo Clinic join forces for AI-driven cardiac care [Yahoo! Finance]Yahoo! Finance
EXAS
Earnings
- 5/8/24 - Miss
EXAS
Sec Filings
- 6/25/24 - Form 11-K
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- EXAS's page on the SEC website